Cell Death and Disease (Aug 2021)

MIR22HG inhibits breast cancer progression by stabilizing LATS2 tumor suppressor

  • Xiaochong Deng,
  • Danrong Ye,
  • Kaiyao Hua,
  • Hongming Song,
  • Qifeng Luo,
  • Amik Munankarmy,
  • Diya Liu,
  • Baian Zhou,
  • Wenfang Zheng,
  • Xiqian Zhou,
  • Changle Ji,
  • Xuehui Wang,
  • Yunhe Yu,
  • Lin Fang

DOI
https://doi.org/10.1038/s41419-021-04105-9
Journal volume & issue
Vol. 12, no. 9
pp. 1 – 10

Abstract

Read online

Abstract The long noncoding RNA called MIR22 host gene (MIR22HG) was previously identified as a tumor suppressor in several cancers. However, the biological function of MIR22HG in breast cancer remains unknown. In this study, we aimed to determine the function and molecular mechanism of MIR22HG in breast cancer progression using transcriptomics and biotechnological techniques. Our results showed that MIR22HG expression was lower in the cancerous tissues than in the paired adjacent normal breast tissues. Additionally, MIR22HG was found to be mainly located in the cytoplasm and acted as a miR-629-5p sponge. Notably, MIR22HG stabilized the expression of large tumor suppressor 2 (LATS2), which promoted the LATS2-dependent phosphorylation of YAP1 and suppressed the expression of its downstream target oncogenes, thereby inhibiting the proliferation and migration of breast cancer cells. Therefore, our findings reveal the MIR22HG-dependent inhibition of breast cancer cell proliferation and migration via the miR-629-5p/LATS2 pathway, providing new insights and identifying novel therapeutic targets for breast cancer treatment.